Research and Markets: Asthma: Modern Therapeutic Targets

DUBLIN, Nov 12, 2010 (BUSINESS WIRE) -- Research and Markets ( has announced the addition of the "Asthma: Modern Therapeutic Targets" book to their offering.

The care of an increasing number of adult and child patients with asthma has become a major task for clinicians, and a growing concern for public health physicians and health care administrators. At the same time, and in response to this situation, a considerable effort is being made in basic and clinical research to develop new treatments. This book looks into the future and assesses the possibilities of a number of new therapies for asthma under exploration and development. A group of distinguished international authors examine the potential of new agents working on various targets that are currently under evaluation, including autocoids and their inhibitors, enzyme-inhibitors, sensory nerves and sensory neuropeptides, and receptors in immunology Asthma: Modern Therapeutic Targets provides physicians with an appreciation of the future directions of treatment. It provides clinical pharmacologists and researchers with an up-to-date insight into advances in this exciting field. This book will also be a valuable tool for researchers in the pharmaceutical industry.

Benefits: Presents a comprehensive review of current treatment options Latest guidelines on clinical management reviewed from an international perspective Provides background on pharmacology and mechanisms of drug action Provides a key resource for individual patient care Readership: Specialists in respiratory medicine, allergy and immunology General physicians Clinical pharmacologists Doctors in training Key Topics Covered: Section I: Autocoids and their receptors in airway diseases Adenosine receptors: novel molecular targets in asthma The role of transforming growth factors in asthma and their potential as a target for therapy The role of transcription factors in asthma: can we modify them for therapeutic purposes? Is IKK a feasible therapeutic target for allergic asthma? Section II: Enzyme inhibitors Protease-activated receptors: targets for therapeutic intervention in asthma Nitric oxide synthase as a therapeutic target in asthma Metalloproteinases and asthma: untried potential for new therapeutic strategies Section III: Sensory nerves and sensory neuropeptides Sensory neuropeptides as innovative targets in asthma Rationale for vanilloid receptor 1 antagonist-based therapies in asthma Section IV: Receptors in immunology Anticytokines and cytokines as asthma therapy Tumour necrosis factor alpha and asthma Are chemokines viable targets for asthma? Antagonism of the chemokine receptor CCR3 as a potential therapeutic treatment for asthma Author: R Polosa, Presidio Ospedaliero Ascoli-Tomaselli, Catania, Italy ST Holgate, Southampton General Hospital, Southampton, UK For more information visit SOURCE: Research and Markets CONTACT: Research and Markets Laura Wood, Senior Manager, U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Copyright Business Wire 2010 -0- KEYWORD: United States

North America